Quick Answer
Vivos Therapeutics, Inc. reported Operating Income Loss of -$11.17 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +35.4% in Operating Income Loss from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.56 million | Q2 2020: -$1.42 million | Q3 2020: -$1.82 million | Q1 2021: -$3.41 million | Q2 2021: -$4.06 million | Q3 2021: -$5.50 million | Q1 2022: -$6.64 million | Q2 2022: -$6.96 million | Q3 2022: -$5.41 million | Q1 2023: -$5.01 million | Q2 2023: -$4.52 million | Q3 2023: -$3.64 million | Q1 2024: -$3.79 million | Q2 2024: -$1.94 million | Q3 2024: -$2.65 million | Q1 2025: -$3.92 million | Q2 2025: -$4.87 million | Q3 2025: -$4.73 million.
- Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Operating Income Loss has declined by 5.6%.
- Historical annual values: Fiscal year 2024: -$11.17 million | Fiscal year 2023: -$17.30 million | Fiscal year 2022: -$25.03 million | Fiscal year 2021: -$20.38 million | Fiscal year 2020: -$12.04 million | Fiscal year 2019: -$10.58 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: